BMS 193885Competitive NPY Y1 receptor antagonist CAS# 679839-66-8 |
- MK-4827
Catalog No.:BCC1761
CAS No.:1038915-60-4
- Iniparib (BSI-201)
Catalog No.:BCC2208
CAS No.:160003-66-7
- AG-14361
Catalog No.:BCC2209
CAS No.:328543-09-5
- PJ34 hydrochloride
Catalog No.:BCC2210
CAS No.:344458-15-7
- Rucaparib (AG-014699,PF-01367338)
Catalog No.:BCC2207
CAS No.:459868-92-9
- Veliparib dihydrochloride
Catalog No.:BCC2076
CAS No.:912445-05-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 679839-66-8 | SDF | Download SDF |
PubChem ID | 56972234 | Appearance | Powder |
Formula | C36H48N4O9 | M.Wt | 680.79 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 20 mM in water and to 100 mM in DMSO | ||
Chemical Name | dimethyl 4-[3-[3-[4-(3-methoxyphenyl)piperidin-1-yl]propylcarbamoylamino]phenyl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate;(2S)-2-hydroxypropanoic acid | ||
SMILES | CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC(=CC=C2)NC(=O)NCCCN3CCC(CC3)C4=CC(=CC=C4)OC)C(=O)OC.CC(C(=O)O)O | ||
Standard InChIKey | BYHJIPSVXAFCDI-WNQIDUERSA-N | ||
Standard InChI | InChI=1S/C33H42N4O6.C3H6O3/c1-21-28(31(38)42-4)30(29(22(2)35-21)32(39)43-5)25-10-6-11-26(19-25)36-33(40)34-15-8-16-37-17-13-23(14-18-37)24-9-7-12-27(20-24)41-3;1-2(4)3(5)6/h6-7,9-12,19-20,23,30,35H,8,13-18H2,1-5H3,(H2,34,36,40);2,4H,1H3,(H,5,6)/t;2-/m.0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Potent, competitive neuropeptide (NPY) Y1 antagonist (Ki = 3.3 nM, IC50 = 5.9 nM) that displays > 47, > 100, > 160, > 160 and > 160-fold selectivity over σ1, α1, Y2, Y4 and Y5 receptors respectively. Reduces food intake and body weight via central Y1 inhibition and is brain penetrant. |
BMS 193885 Dilution Calculator
BMS 193885 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.4689 mL | 7.3444 mL | 14.6888 mL | 29.3776 mL | 36.722 mL |
5 mM | 0.2938 mL | 1.4689 mL | 2.9378 mL | 5.8755 mL | 7.3444 mL |
10 mM | 0.1469 mL | 0.7344 mL | 1.4689 mL | 2.9378 mL | 3.6722 mL |
50 mM | 0.0294 mL | 0.1469 mL | 0.2938 mL | 0.5876 mL | 0.7344 mL |
100 mM | 0.0147 mL | 0.0734 mL | 0.1469 mL | 0.2938 mL | 0.3672 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
BMS-193885 is a potent and selective neuropeptide Y1 receptor antagonist with IC50 of 5.9nM.
Neuropeptide Y receptor 1 is G-protein coupled receptors and implicated in the modulation of food intake and energy homeostasis. Neuropeptide Y1 is expressed in many tissues including the hippocampus, hypothalamus, amygdala and the cortex of the brain as well as in peripheral tissues heart, kidney, skeletal muscle. The localization and expression suggests their involvement in the regulation of food intake and body weight.
In cellular culture, BMS-193885 displayed functional antagonism of Neuropeptide Y1 in a
forskolin-stimulated c-AMP production assay using CHO cells expressing the human Y(1) receptor 1.
In vivo, administration of BMS-193885 at a dosage of 10mg/kg leads to 1h neuropeptide Y-induced food intake in rat and the spontaneous overnight food consumpetion 2 . Chronic administration of BMS-193885 (10 mg/kg) i.p. for 44 days significantly reduced food intake and the rate of body weight gain as compared to their control without developing tolerance or affecting water intake 2.
References:
1. Poindexter GS, Bruce MA, LeBoulluec KL, et al. Dihydropyridine neuropeptide Y Y(1) receptor antagonists. Bioorganic & medicinal chemistry letters. 2002;12(3):379-382.
2. Antal-Zimanyi I, Bruce MA, Leboulluec KL, et al. Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist. European journal of pharmacology. 2008;590(1-3):224-232.
- N-(15-Methyl-9-hexadecenoyl)taurine
Catalog No.:BCN1754
CAS No.:679834-30-1
- N-(5,8,11,14-Eicosatetraenoyl)taurine
Catalog No.:BCN1755
CAS No.:679834-28-7
- Aurantio-obtusin
Catalog No.:BCN1222
CAS No.:67979-25-3
- Sodium Danshensu
Catalog No.:BCN5952
CAS No.:67920-52-9
- 1,6-Dihydro-4,7'-epoxy-1-methoxy-3',4'-methylenedioxy-6-oxo-3,8'-lignan
Catalog No.:BCN6584
CAS No.:67920-48-3
- Mesaconine
Catalog No.:BCC8339
CAS No.:6792-09-2
- Macusine B
Catalog No.:BCN6471
CAS No.:6792-07-0
- Homobaldrinal
Catalog No.:BCN2681
CAS No.:67910-07-0
- Dehydroevodiamine
Catalog No.:BCN2974
CAS No.:67909-49-3
- Aluminum n-octacosoxide
Catalog No.:BCC8099
CAS No.:67905-27-5
- Ambrox
Catalog No.:BCN6907
CAS No.:6790-58-5
- Scutebarbatine K
Catalog No.:BCN3223
CAS No.:960302-86-7
- Sodium citrate
Catalog No.:BCC7588
CAS No.:68-04-2
- Vitamin B12
Catalog No.:BCC4878
CAS No.:68-19-9
- Norethindrone
Catalog No.:BCC4811
CAS No.:68-22-4
- Vitamin A
Catalog No.:BCN8349
CAS No.:68-26-8
- Sulfadiazine
Catalog No.:BCC3859
CAS No.:68-35-9
- Hydroxyzine
Catalog No.:BCC5209
CAS No.:68-88-2
- Metamizole sodium
Catalog No.:BCC9024
CAS No.:68-89-3
- Hypoxanthine
Catalog No.:BCC5324
CAS No.:68-94-0
- Ac-Pro-OH
Catalog No.:BCC3017
CAS No.:68-95-1
- Hydroxyprogesterone
Catalog No.:BCC8996
CAS No.:68-96-2
- Magnocurarine
Catalog No.:BCN3839
CAS No.:6801-40-7
- Pulsatilla saponin H
Catalog No.:BCN8181
CAS No.:68027-14-5
Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist.[Pubmed:18573246]
Eur J Pharmacol. 2008 Aug 20;590(1-3):224-32.
Treatment of obesity is still a large unmet medical need. Neuropeptide Y is the most potent orexigenic peptide in the animal kingdom. Its five cloned G-protein couple receptors are all implicated in the regulation of energy homeostasis evidenced by overexpression or deletion of neuropeptide Y or its receptors. Neuropeptide Y most likely exerts its orexigenic activity via the neuropeptide Y(1) and neuropeptide Y(5) receptors, although the involvement of the neuropeptide Y(2) and neuropeptide Y(4) receptors are also gaining importance. The lack of potent, selective, and brain penetrable pharmacologic agents at these receptors made our understanding of the modulation of food intake by neuropeptide Y-ergic agents elusive. BMS-193885 (1,4-dihydro-[3-[[[[3-[4-(3-methoxyphenyl)-1-piperidinyl]propyl]amino] carbonyl]amino]phenyl]-2,6-dimethyl-3,5-pyridinedicarboxylic acid, dimethyl ester) is a potent and selective neuropeptide Y(1) receptor antagonist. BMS-193885 has 3.3 nM affinity at the neuropeptide Y(1) receptor, acting competitively at the neuropeptide Y binding site. BMS-193885 increased the K(d) of [(125)I]PeptideYY from 0.35 nM to 0.65 nM without changing the B(max) (0.16 pmol/mg of protein) in SK-N-MC cells that endogenously express the neuropeptide Y(1) receptor. It is also found to be a full antagonist with an apparent K(b) of 4.5 nM measured by reversal of forskolin (FK)-stimulated inhibition of cAMP production by neuropeptide Y. Pharmacological profiling showed that BMS-193885 has no appreciable affinity at the other neuropeptide Y receptors, and is also 200-fold less potent at the alpha(2) adrenergic receptor. Testing the compound in a panel of 70 G-protein coupled receptors and ion channels resulted in at least 200-fold or greater selectivity, with the exception of the sigma(1) receptor, where the selectivity was 100-fold. When administered intracerebroventricularly or directly into the paraventricular nucleus of the hypothalamus, it blocked neuropeptide Y-induced food intake in rats. Intraperitoneal administration of BMS-193885 (10 mg/kg) also reduced one-hour neuropeptide Y-induced food intake in satiated rats, as well as spontaneous overnight food consumption. Chronic administration of BMS-193885 (10 mg/kg) i.p. for 44 days significantly reduced food intake and the rate of body weight gain compared to vehicle treated control without developing tolerance or affecting water intake. These results provide supporting evidence that BMS-193885 reduces food intake and body weight via inhibition of the central neuropeptide Y(1) receptor. BMS-193885 has no significant effect of locomotor activity up to 20 mg/kg dose after 1 h of treatment. It also showed no activity in the elevated plus maze when tested after i.p. and i.c.v. administration, indicating that reduction of food intake is unrelated to anxious behavior. BMS-193885 has good systemic bioavailability and brain penetration, but lacks oral bioavailability. The compound had no serious cardiovascular adverse effect in rats and dogs up to 30 and 10 mg/kg dose, respectively, when dosed intravenously. These data demonstrate that BMS-193885 is a potent, selective, brain penetrant Y(1) receptor antagonist that reduces food intake and body weight in animal models of obesity both after acute and chronic administration. Taken together the data suggest that a potent and selective neuropeptide Y(1) receptor antagonist might be an efficacious treatment for obesity in humans.
Dihydropyridine neuropeptide Y Y1 receptor antagonists 2. bioisosteric urea replacements.[Pubmed:14723969]
Bioorg Med Chem. 2004 Jan 15;12(2):507-21.
Structure-activity studies around the urea linkage in BMS-193885 (4a) identified the cyanoguanidine moiety as an effective urea replacement in a series of dihydropyridine NPY Y(1) receptor antagonists. In comparison to urea 4a (K(i)=3.3 nM), cyanoguanidine 20 (BMS-205749) displayed similar binding potency at the Y(1) receptor (K(i)=5.1 nM) and full functional antagonism (K(b)=2.6 nM) in SK-N-MC cells. Cyanoguanidine 20 also demonstrated improved permeability properties in Caco-2 cells in comparison to urea 4a (43 vs 19 nm/s).